Biogen CEO Blames Confusion, Misinfo For Slow Alzheimer’s Drug Launch
Biogen CEO Michel Vounatsos said Alzheimer's drug Aduhelm has experienced a slower launch than anticipated because of the controversy surrounding whether it works and how it was approved. Hemophilia drugs, anti-covid drug lenzilumab, digital clinical trials and more are among other news.